Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recordati SpAMIL:REC +0.19%98 EV-to-OCF is 19.23 as of Jul. 31, 2026, which is 18% below its 10-year median of 23.56. GuruFocus rates MIL:REC with a GF Score™ of 98/100 and a GF Value™ of €61.09 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Recordati SpA ranks worse than 68.15% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Recordati SpA's Enterprise Value is €12,397 Mil.
Recordati SpA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €645 Mil. Therefore, Recordati SpA's EV-to-OCF for today is 19.23.
The historical rank and industry rank for Recordati SpA's EV-to-OCF or its related term are showing as below:
MIL:REC'
s EV-to-OCF Range Over the Past 10 Years
Min: 17.41 Med: 23.56 Max: 36.15
Current: 19.23
During the past 13 years, the highest EV-to-OCF of Recordati SpA was 36.15. The lowest was 17.41. And the median was 23.56.
MIL:REC's EV-to-OCF is ranked worse than 68.15% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.725
vs MIL:REC: 19.23
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Recordati SpA's PE Ratio (TTM) for today is calculated as:
Recordati SpA's share price for today is €51.50.
Recordati SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.380.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Recordati SpA EV-to-OCF Related Terms
Recordati SpA EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Recordati SpA's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Recordati SpA's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Recordati SpA's EV-to-OCF falls into.
Recordati SpA's current Enterprise Value is €12,397 Mil.
Recordati SpA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €645 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recordati SpA (MIL:REC) has a EV-to-OCF of 19.23 as of Jul. 31, 2026. This is 18% below median its historical median of 23.56. Over the past decade, Recordati SpA's EV-to-OCF has ranged from 17.41 to 36.15. According to the industry distribution chart, Recordati SpA ranks #687 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 68.2%.
Is Recordati SpA's EV-to-OCF too high?
Recordati SpA's current EV-to-OCF of 19.23 is 18% below median its 10-year median of 23.56. Over the past 10 years, this metric has ranged from a low of 17.41 to a high of 36.15. The Drug Manufacturers industry median EV-to-OCF is 10.73. Recordati SpA's value of 19.23 is 79.3% above this industry median. Based on the distribution chart, Recordati SpA ranks #687 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Recordati SpA has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's EV-to-OCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #687 out of 1008 companies for EV-to-OCF. This places Recordati SpA in the lower half of its industry. The industry median EV-to-OCF is 10.73. Recordati SpA's value of 19.23 is 79.3% above this benchmark. Historically, Recordati SpA's own EV-to-OCF has ranged from 17.41 to 36.15 over the past decade. While the company's 10-year median is 23.56 vs. the industry median of 10.73, Recordati SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.73, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current EV-to-OCF of 19.23 is 79.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current EV-to-OCF is 19.23, which is 18% below median its own 10-year median of 23.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €61.09, compared to a current price of €51.50 — trading 15.7% below its estimated fair value. The current EV-to-OCF is 19.23, which is 18% below median its 10-year median of 23.56 and 79.3% above the Drug Manufacturers industry median of 10.73. Recordati SpA's overall GF Score™ is 98/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current EV-to-OCF is 19.23 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €51.50 is trading 15.7% below its estimated GF Value™ of €61.09.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
EV-to-OCF: 19.23 (18% below median its 10-year median of 23.56)
GF Value™: €61.09 vs. price of €51.50 (15.7% below fair value)
Industry Position: 79.3% above the Drug Manufacturers median (#687 of 1008)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
98GF Score
Get the complete analysis for MIL:REC
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 
